German Agency Questions Benefit of Empliciti Reported in Multiple Myeloma Study
Empliciti (elotuzumab), a monoclonal antibody, is approved in both the…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Biotech Companies Partner with Memorial Sloan Kettering to Develop Multiple Myeloma Immunotherapy Program
Juno Therapeutics and privately held biotech…
Relapsed, Refractory Multiple Myeloma Progression Free Survival Prolonged with Drug Combo
Elotuzumab in combination with bortezomib and dexamethasone prolongs…
MMRF, University of Michigan to Begin Personalized Multiple Myeloma Profiling Initiative
The Multiple Myeloma Research Foundation (MMRF) and the…
Myeloma Therapies Advancing Rapidly, Says Expert at Sloan Kettering
In a video posted on Healio’s Hematology-Oncology…
Thalidomide Seen as Superior Pre-Stem Cell Transplant Therapy for Multiple Myeloma
A three-drug combination that includes thalidomide, in place of cyclophosphamide,…
